Concepedia
Statistics
Publications
5
Citations
57
H-Index
Active since
2019
Affiliations
Institut Gustave Roussy(Current)
National Taiwan University Hospital
Dana-Farber Cancer Institute
St George Hospital
AstraZeneca (Spain)
D. Planchard is an author at Institut Gustave Roussy specializing in oncology, egfr inhibition, and lung cancer pharmacotherapy.
Publications per year
2019–2025
975P Trastuzumab deruxtecan in patients (pts) with HER2-overexpressing (HER2-OE) metastatic non-small cell lung cancer (NSCLC): Results from the DESTINY-Lung01 trial
E.F. Smit, E. Felip, D. Uprety et al. · Annals of Oncology · 2022 · 16 citations · Full text
Medicine, Oncology, Pharmacology +14
Osimertinib vs comparator EGFR-TKI as first-line treatment for EGFRm advanced NSCLC (FLAURA): Final overall survival analysis
Byoung Chul Cho, Y. Ohe, C. Zhou et al. · Annals of Oncology · 2019 · 11 citations · Full text
Medicine, Oncology, Pharmacology +8
PL03.13 Osimertinib With/Without Platinum-Based Chemotherapy as First-line Treatment in Patients with EGFRm Advanced NSCLC (FLAURA2)
Pasi A. Jänne, D. Planchard, Ying Cheng et al. · Journal of Thoracic Oncology · 2023 · 10 citations · Full text
OA16.05 Trastuzumab Deruxtecan Monotherapy in Pretreated HER2-overexpressing Nonsquamous Non-Small Cell Lung Cancer: DESTINY-Lung03 Part 1
D. Planchard, H.R. Kim, T. Suksombooncharoen et al. · Journal of Thoracic Oncology · 2024 · 10 citations · Full text
PL02.06 First-Line Osimertinib + Chemotherapy Versus Osimertinib Monotherapy in EGFRm Advanced NSCLC: FLAURA2 Final Overall Survival
D. Planchard, P.A. Jänne, K. Kobayashi et al. · Journal of Thoracic Oncology · 2025 · 10 citations
1–5 of 5